Phase 3 long-term safety, tolerability, and effectiveness of lurasidone in subjects with schizophrenia or schizoaffective disorder: A randomized, active comparator-controlled trial.

Trial Profile

Phase 3 long-term safety, tolerability, and effectiveness of lurasidone in subjects with schizophrenia or schizoaffective disorder: A randomized, active comparator-controlled trial.

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Sep 2016

At a glance

  • Drugs Lurasidone (Primary) ; Risperidone
  • Indications Schizoaffective disorder; Schizophrenia
  • Focus Adverse reactions; Registrational
  • Sponsors Sumitomo Dainippon Pharma; Sunovion Pharmaceuticals
  • Most Recent Events

    • 20 Sep 2016 Results of post hoc analysis from this and Pearl-3 study (Profile 234648), presented at the 29th Annual Congress of the European College of Neuropsychopharmacology.
    • 31 Mar 2015 Post-hoc analysis of pooled data from this and another phase III trial (CT profile 700234648) presented at the 23rd European Congress of Psychiatry (EPA) 2016, according to a Sunovian Pharmaceuticals media release.
    • 21 Oct 2014 Post hoc analysis comparing the effect of lurasidone versus risperidone on metabolic syndrome status in patients with schizophrenia presented at the 27th Annual Congress of the European College of Neuropsychopharmacology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top